Skip to main
PEPG
PEPG logo

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

The analysis indicates that PepGen Inc. has demonstrated a robust dose-dependent increase in splicing correction in its FREEDOM-DM1 trial, particularly noting a nearly four-fold increase in oligonucleotide enrichment in muscle tissue as the dosage increased from 5 mg/kg to 10 mg/kg. This efficacy data, with a splicing correction rate of 29.1%, exceeds the generally accepted therapeutic threshold of 25-27%, reinforcing the potential therapeutic benefits of the Enhanced Delivery Oligonucleotide (EDO) platform. Furthermore, the absence of safety issues reported while testing higher doses signals a strong outlook for PepGen’s pipeline products, particularly PGN-EDO51, which could lead to a best-in-class position within the DM1 landscape.

Bears say

PepGen Inc. reported a significant net loss of $22 million or $0.68 per share in the fourth quarter of 2024, which raises concerns about its financial stability as it continues to develop its pipeline products, particularly PGN-EDO51. The company has lowered its probability of success for PGN-EDO51 from 40% to 25% due to safety concerns regarding kidney function, particularly related to reductions in estimated glomerular filtration rate (eGFR), which diminishes investor confidence in its clinical viability and potential market success. Additionally, substantial risks remain regarding the potential failure of PGN-EDO51 in clinical trials, securing regulatory approvals in the US and EU, and meeting peak commercial revenue expectations, all of which could adversely impact the company's financial performance and outlook.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.